InvestorsHub Logo
Followers 24
Posts 1336
Boards Moderated 0
Alias Born 11/15/2016

Re: None

Thursday, 02/03/2022 5:52:13 PM

Thursday, February 03, 2022 5:52:13 PM

Post# of 3867
We will see where this news leads us, I haven’t researched This guy yet.




9:00a ET 2/3/2022 - Globe Newswire
Nexien BioPharma Engages Dr. Benedikt Schoser as Advisor
Mentioned: NXEN
Nexien BioPharma Inc. (OTCQB: NXEN) ("Nexien" or the "Company") today announced that it has retained Dr. Benedikt Schoser as an advisor to the Company. Dr. Schoser, who has previously served as a scientific advisor to the Company, is senior consultant at the Friedrich-Baur Institute, Department of Neurology at the Ludwig-Maximilians-University of Munich, Germany's major national referral center for rare neuromuscular diseases, and is considered one of the world's top researchers in myotonia and the treatment of myotonic dystrophy. The Company also retained regulatory counsel and is initiating discussions with a pharmaceutical company to pursue formulation development. Richard Greenberg, Nexien's CEO and Chairman of the Board, stated, "We are excited to be establishing a team to address myotonic dystrophy and myotonia. The successful completion of our recent financing enables us to recommence our myotonic dystrophy research." Greenberg added, "Nexien has already been granted a United States patent for the treatment of dystrophies and myotonia and looks forward to benefiting from the team's knowledge regarding myotonic dystrophy, while seeking to advance a drug development strategy to treat myotonic dystrophy and myotonia."
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NXEN News